Previous 10 | Next 10 |
BOSTON , Oct. 21, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processin...
Privately held Boehringer Ingelheim announces the start of enrollment in a Phase 2 clinical trial evaluating different doses of BI 1265162, an epithelial sodium channel inhibitor delivered via the Respimat inhaler, in cystic fibrosis (CF) patients regardless of their mutation status. M...
BOSTON , Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processi...
BOSTON , Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein proce...
Proteostasis Therapeutics (NASDAQ: PTI ): Q2 GAAP EPS of -$0.39. More news on: Proteostasis Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BOSTON , Aug. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processin...
The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' ( PTI -1.6% ) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous ...
BOSTON , July 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that the first patient has been dosed in t...
BOSTON , July 23, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein ...
InflaRx N.V. (NASDAQ: IFRX ) -87% after IFX-1 flunks mid-stage study. More news on: InflaRx N.V., GameStop Corp., ChemoCentryx, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Yumanity Therapeutics Inc Com Company Name:
PTI Stock Symbol:
NASDAQ Market:
Brawijaya University develops GIS-based IoT for disaster mitigation Malang, East Java, Indonesia, Sept 30, 2022 - (ACN Newswire) - Brawijaya University has developed an Internet of Things (IoT) technology based on the Geographic Information System (GIS) to mitigate disasters i...
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio PR Newswire BOSTON , Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI)...
Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 2...